Abstract
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the main actor in secondary prevention of recurrent coronary ischemic events and stent thrombosis. For this exact purpose the combination of two antiplatelet molecules have proven efficacy and superiority compared to monotherapy, aspirin alone, but this comes with an increased risk of major and potentially fatal bleedings, making the choice of the molecules and especially the duration of treatment a true challenge for every cardiologist. We are going to discuss some of the main factors that play a role in the decision, and the most important trials that studied the subject.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
